AU5453898A - Methods of inhibiting protein degradation to combat muscle wasting - Google Patents

Methods of inhibiting protein degradation to combat muscle wasting

Info

Publication number
AU5453898A
AU5453898A AU54538/98A AU5453898A AU5453898A AU 5453898 A AU5453898 A AU 5453898A AU 54538/98 A AU54538/98 A AU 54538/98A AU 5453898 A AU5453898 A AU 5453898A AU 5453898 A AU5453898 A AU 5453898A
Authority
AU
Australia
Prior art keywords
methods
protein degradation
muscle wasting
inhibiting protein
combat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54538/98A
Inventor
Vered Bhoite-Solomon
Alfred L. Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of AU5453898A publication Critical patent/AU5453898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU54538/98A 1996-11-25 1997-11-25 Methods of inhibiting protein degradation to combat muscle wasting Abandoned AU5453898A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75571396A 1996-11-25 1996-11-25
US08755713 1996-11-25
PCT/US1997/021421 WO1998023283A1 (en) 1996-11-25 1997-11-25 Methods of inhibiting protein degradation to combat muscle wasting

Publications (1)

Publication Number Publication Date
AU5453898A true AU5453898A (en) 1998-06-22

Family

ID=25040334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54538/98A Abandoned AU5453898A (en) 1996-11-25 1997-11-25 Methods of inhibiting protein degradation to combat muscle wasting

Country Status (2)

Country Link
AU (1) AU5453898A (en)
WO (1) WO1998023283A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3474199A (en) * 1998-04-07 1999-10-25 Regeneron Pharmaceuticals, Inc. Method of identifying agents that block muscle atrophy
AU2605600A (en) * 1999-01-11 2000-08-01 Mindset Biopharmaceuticals (Usa) Inc. Methods for regulating the stability of recombinant proteins and products usefultherein
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US6706505B1 (en) 2000-03-08 2004-03-16 Amgen Inc Human E3α ubiquitin ligase family
US7575881B2 (en) 2002-03-21 2009-08-18 California Institute Of Technology Modulation of nitric oxide signaling through signaling through specific regulation by arginylation and the N-end rule pathway
WO2003079999A2 (en) * 2002-03-21 2003-10-02 California Institute Of Technology Modulation of angiogenesis through targeting of arginyl transferase (ate1)
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP3549595A4 (en) * 2016-12-05 2020-07-22 Otsuka Pharmaceutical Co., Ltd. Amyotrophy inhibiting composition
WO2021060884A1 (en) * 2019-09-24 2021-04-01 마이오텍사이언스 주식회사 Pharmaceutical composition for preventing or treating sarcopenia containing non-natural amino acid derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein

Also Published As

Publication number Publication date
WO1998023283A1 (en) 1998-06-04

Similar Documents

Publication Publication Date Title
AU7698698A (en) Methods and compositions for targeting compounds to muscle
AU7905894A (en) Treatment of poultry
AU2747497A (en) Compositions and methods for antisense inhibition of protein translation
EP1033994A4 (en) Methods of preparation of bioginkgo
AU3549397A (en) Over-expression of proteins
AU3552697A (en) Novel treatment of leptine resistance
AU5453898A (en) Methods of inhibiting protein degradation to combat muscle wasting
AU6450398A (en) Sr-bi regulatory sequences and therapeutic methods of use
ZA983065B (en) Inhibitors of protein farnesyltranferase
PL332282A1 (en) Application of proteins as factors against autoimmunological diseases
AU5763398A (en) Nonlethal weapons
PL330550A1 (en) Novel aromatic ribose-substituted derivatives, method of obtaining them and their application as therapeutic agents
AU5148098A (en) Human eosinophil-derived basic protein
AU5621798A (en) Human pathogenesis-related protein
AU5131699A (en) Cryogranulation of activated protein c
AUPN976596A0 (en) Stimulation of host defence mechanisms
AU5219798A (en) Gpi-ceruloplasmin, analogs thereof, and methods of use
PL334186A1 (en) Derivatives of cyclopeptides
AU9538698A (en) Mixture of benzothiophene derivatives
IL118781A0 (en) Preparation of N-protected 4-ketoproline derivatives
AUPO124196A0 (en) Method of ground treatment
AUPO421596A0 (en) Method of maintaining turf
AU3174497A (en) Use of pyrrolopyrimidines to combat pests
AU5611398A (en) Method of treating or inhibiting neutropenia
AU9553598A (en) Method of preparation of products which absorb water intermolecularly